Abstract
Merck has begun the defence of its anti-arthritis drug rofecoxib (Vioxx) in the Federal Court of Australia, amid revelations that it lobbied to quash similar legal action in Britain, and as a publisher apologised for a journal sponsored by the company.
Original language | English |
---|---|
Pages (from-to) | b1914-b1914 |
Number of pages | 1 |
Journal | BMJ (Clinical research ed.) |
Volume | 338 |
DOIs |
|
Publication status | Published - 2009 |